ADMA Biologics Q3 Revenues Hit $134M, EPS 16 Cents Beat Estimate
ADMA Biologics reported third-quarter 2025 adjusted earnings per share of $0.16 and revenue of $134 million, surpassing consensus by 3.2%. The company forecasts 49.1% earnings growth for 2026, more than triple the industry’s 13.2% rate.
1. Q3 2025 Financial Results
ADMA Biologics delivered adjusted earnings per share of $0.16 in third-quarter 2025, alongside revenue of $134 million. Both metrics exceeded consensus estimates, with revenue beating forecasts by 3.2%, reflecting strong immunoglobulin product demand.
2. Growth Outlook and Ranking
The company projects 49.1% earnings growth in 2026 versus a 13.2% industry average, driven by expanded commercial capacity and new product launches. ADMA Biologics holds a Zacks Rank #2, indicating positive analyst sentiment on its near-term prospects.
Related News
PERI
Perion Q1 Revenue Rises 1% as Outmax AI Spend Soars 300% and CTV Spend Jumps 68%
PERI•
INTC
Nvidia’s $91B AI Forecast, $80B Buyback Ramps Up Pressure on Intel
INTC•
PII
Polaris Launches $9,999 RANGER 500 and Installs 8,000 m² Solar Array
PII•
AMZN
Amazon MGM Invests $75M in Melania Documentary Despite Political Scrutiny
AMZN•
MS
Morgan Stanley to Co-Lead SpaceX’s $1.75T Nasdaq IPO with Four Banks
MS•
Sources
F